Naltrexone
| Naltrexone | |
|---|---|
| Salts [] | |
|---|---|
| Naltrexone hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 341.40 g/mol [1] |
| Appearance | Crystals from acetone [1] |
| Melting point | 168-170 °C [1] |
| Decomposition | Hazardous decomposition products formed under fire conditions - Carbon oxides, nitrogen oxides (NOx), hydrogen chloride gas. /Naltrexone hydrochloride/ [1] |
| Solubility | 100 mg/mL (as hydrochloride salt) [1] |
| Predicted LogP | 1.9 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C20H23NO4 |
| IUPAC name | (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one |
| SMILES | C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O |
| InChI | InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1 |
| InChIKey | DQCKKXVULJGBQN-XFWGSAIBSA-N |
| CAS number | 16590-41-3 |
| UNII | 5S6W795CQM |
| PubChem CID | 5360515 |
| Pharmacokinetics[] | |
|---|---|
| Onset | 30 minutes |
| Elimination half-life | Oral (Revia):, • Naltrexone: 4 hours, • 6β-Naltrexol: 13 hours, Oral (Contrave):, • Naltrexone: 5 hours, Intramuscular injection (Vivitrol):, • Naltrexone: 5–10 days, • 6β-Naltrexol: 5–10 days[3][4][5] |
| Duration of action | >72 hours |
| Metabolism | Liver (non-CYP450)[6] |
| Excretion | Urine |
| Routes of administration | By mouth, intramuscular, subcutaneous implant |
| Toxicity [] | |
|---|---|
| LD50 | Guinea: - pig oral: 1.49 g/kg Monkey: - oral: 3.0 g/kg Mouse: - oral: 1.1-1.55 Rat: - oral: 1.45 g/kg [1] |
Naltrexone (also known as Vivitrol, Vivitrex, Celupan, Naltrexona, N-Cyclopropylmethylnoroxymorphone, Naltrexonum, Nemexin, N-Cyclopropylmethyl-14-hydroxydihydromorphinone, 17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one or 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one) is a opioid antagonist substance of the 2-benzylpiperidine class.
Chemistry
Salts []
Stereochemistry []
Naltrexone is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Naltrexone matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- other nervous system drugs (N07)
- drugs used in addictive disorders (N07B)
- drugs used in alcohol dependence (N07BB)
- (N07BB04)
- naltrexone (N07BB04)
MeSH Classification
Mechanism of action []
Naltrexone is a pure opiate antagonist and has little or no agonist activity. The mechanism of action of naltrexone in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data. Naltrexone is thought to act as a competitive antagonist at mc, κ, and δ receptors in the CNS, with the highest affintiy for the μ receptor. Naltrexone competitively binds to such receptors and may block the effects of endogenous opioids. This leads to the antagonization of most of the subjective and objective effects of opiates, including respiratory depression, miosis, euphoria, and drug craving. The major metabolite of naltrexone, 6-β-naltrexol, is also an opiate antagonist and may contribute to the antagonistic activity of the drug. [1]
Medical side effects []
240 side effects listed on drug labels in SIDER 4.1 (naltrexone).
- Nausea
- Depression
- Headache
- Frequent headaches
- Dizziness
- Syncope
- Asthenia
- Fatigue
- Nervousness
- Tension
- Vomiting
- Injection site reaction
- Insomnia
- Difficulty sleeping
- Anxiety
- Anxiety aggravated
- Anxiety NEC
- Somnolence
- Suicide attempt
- Abdominal pain
- Abdominal cramps
- Gastrointestinal pain
- Alcoholism
- Alcohol abuse
- Dementia Alzheimer's type
- Anaphylactic shock
- Decreased appetite
- Appetite absent
- Chest pain
- Confusional state
- Feeling abnormal
- Malaise
- Diarrhoea
- Loose stools
- Dyspnoea
- Dermatitis
- Rash
- Hallucination
- Hepatitis
- Hypersensitivity
- Obesity
- Palpitations
- Retinal artery occlusion
- Withdrawal syndrome
- Completed suicide
- Tremor
- Purpura
- Idiopathic thrombocytopenic purpura
- Agitation
- Hyperkinesia
- Drug withdrawal syndrome
- Discomfort
- Ill-defined disorder
- Myalgia
- Musculoskeletal discomfort
- Arthralgia
- Thinking abnormal
- Mental disability
- Euphoric mood
- Suicidal ideation
- Drug dependence
- Menopausal symptoms
- Hot flush
- Hyperhidrosis
- Blood pressure fluctuation
- Abortion missed
- Pancreatitis acute
- Alopecia
- Angina pectoris
- Angina unstable
- Angioedema
- Appetite disorder
- Arthritis
- Atrial fibrillation
- Back pain
- Mental disorder
- Bronchitis
- Cellulitis
- Cholelithiasis
- Colitis
- Infection
- Conjunctivitis
- Connective tissue disorder
- Constipation
- Arteriosclerosis coronary artery
- Cough
- Libido decreased
- Disturbance in sexual arousal
- Dehydration
- Delirium
- Dysgeusia
- Oedema
- Epistaxis
- Eye disorder
- Body temperature increased
- Flatulence
- Excessive flatulence
- Gastroenteritis
- Gastrooesophageal reflux disease
- Gastrointestinal disorder
- Gastrointestinal haemorrhage
- Seasonal allergy
- Rhinitis seasonal
- Cardiac disorder
- Cardiac failure congestive
- Heat exhaustion
- Heat stroke
- Haemorrhoids
- Hepatitis C
- Oral herpes
- Dysphonia
- Hypercholesterolaemia
- Hypertension
- Immune system disorder
- Influenza
- Irritability
- Laryngitis
- Lethargy
- Chronic obstructive pulmonary disease
- Bronchial hyperreactivity
- Mediastinal disorder
- Muscle spasms
- Muscle rigidity
- Myocardial infarction
- Acute coronary syndrome
- Nasal congestion
- Nasopharyngitis
- Rhinorrhoea
- Nervous system disorder
- Night sweats
- Nightmare
- Nodule
- Obsessive-compulsive disorder
- Pain
- Ache
- Pain in extremity
- Ileus paralytic
- Paraesthesia
- Pharyngitis
- Phlebitis
- Pneumonia
- Pregnancy
- Pruritus
- Pulmonary embolism
- Convulsion
- Pharyngitis streptococcal
- Sinus headache
- Sinusitis
- Sneezing
- Swelling
- Shock
- Loss of consciousness
- Tachycardia
- Tinea pedis
- Tinnitus
- Toothache
- Ulcer
- Upper respiratory tract infection
- Urinary tract infection
- Urticaria
- Angiopathy
- Weight increased
- Weight decreased
- Dry mouth
- Yawning
- Muscle strain
- Chills
- Rigors
- Panic attack
- Cholecystitis acute
- Lymphadenitis
- Deep vein thrombosis
- Migraine
- Gamma-glutamyltransferase increased
- Injection site pain
- Injection site tenderness
- Aspartate aminotransferase increased
- Alanine aminotransferase increased
- Sinus congestion
- Joint stiffness
- Miliaria
- Malnutrition
- Skin disorder
- Musculoskeletal stiffness
- Stiffness
- Muscle twitching
- Chest discomfort
- Increased appetite
- Abdominal discomfort
- Upset stomach
- Gastrointestinal tract irritation
- Abdominal pain upper
- Abdominal pain lower
- Disorientation
- Disturbance in attention
- Ejaculation delayed
- Abnormal dreams
- Bad dreams
- Seborrhoeic dermatitis
- Poor quality sleep
- Hepatotoxicity
- Alcohol withdrawal syndrome
- Groin pain
- Frequent bowel movements
- Thirst
- Oropharyngeal discomfort
- Oropharyngeal pain
- Perirectal abscess
- Hepatobiliary disease
- Induration
- Vision blurred
- Depressed mood
- Platelet count decreased
- Crying
- Tearfulness
- Peripheral coldness
- Energy increased
- Lymphadenopathy
- Blood pressure increased
- Tooth abscess
- Injection site haemorrhage
- Injection site bruising
- Injection site induration
- Face oedema
- Sexual dysfunction
- White blood cell count increased
- Infestation
- Sleep disorder
- Injection site pruritus
- Hepatic enzyme increased
- Laryngeal pain
- Blood creatinine normal
- Sluggishness
- Ischaemic stroke
- Intracranial aneurysm
- Mental retardation
- Psychotic disorder
- Paranoia
- Rash papular
- Eosinophilic pneumonia
Indications
- Alcoholism
- Dependence on opiates
Experience reports
Erowid
There are currently 23 experience reports involving naltrexone on Erowid: []- "Strapped to the Bed and Given IV Benzos" by Nikoled
- "Self-Imposed Ultra Rapid Detox" by munkyjuce69
- "Rapid Withdrawal Experiment" by Orin
- "Eager to Try It for Alcohol Abuse" by zcaz
- "Sometimes It Makes Me Happy" by Nate
- "The Most Uncomfortable That I Have Ever Been" by MD101
- "Precipitated Withdrawal" by The Weez
- "Real Buzzkill Tech" by Gleetnorx
- "Antagonising Pain" by phoenix
- "Wonderful at Low Dose" by Luxeffexor
- "Endorphin Power" by TheHivemind
- "Rapid Detox, Only Miserable for 2-3 Days" by Einwolff
- "The Sinclair Method" by Goin4More
- "Convulsions From Hell" by Tmannole
- "I Brought This Horror on Myself" by Bulkspin
- "Bad Idea" by Pharmacist
- "Death in the Air" by 860
- "Busting the Blockade" by quackntrash
- "Sinclair Method Failure" by Sydney
- "Not to Be Confused With Suboxone" by Mike
- "Curse to a Blessing" by WaveMan
- "Side Effect of Chewing" by Seully
- "I Was Violently Ill" by montana
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5360515, Naltrexone. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5360515
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Naltrexone. UNII: 5S6W795CQM. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/5S6W795CQM
Revia (naltrexone hydrochloride tablets USP50 mgOpioid Antagonist. DailyMed. 24 April 2015. https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=172953
Contrave Extended-Release – naltrexone hydrochloride and bupropion hydrochloride tablet, extended release. DailyMed. 4 November 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b
Vivitrol- naltrexone kit. DailyMed. 10 March 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd11c435-b0f0-4bb9-ae78-60f101f3703f
Sevarino KA, Kosten TR. Opiate Receptors and Antagonists. Humana Press. 2009.
Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration (TGA). 21 June 2022. https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017
RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 15:32:20 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 15:32:16 |
| erowid | ok | 2026-11-20 15:32:18 |
| gsrs | ok | 2026-11-20 15:32:17 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014842) | 2026-11-20 15:32:16 |
| kegg | ok | 2026-11-20 15:32:19 |
| pubchem | ok | 2026-11-20 15:32:15 |
| missing (no r/tripreports posts mention it) | 2026-11-20 15:32:16 | |
| sider | ok | 2026-11-20 15:32:16 |
| structure | ok | 2026-11-20 15:32:16 |
| wikipedia | ok | 2026-11-20 15:32:16 |